All lobbying filings

Avenue Solutions

Avenue Solutions filed a Q1 report for Jazz Pharmaceuticals, Inc. on April 20, 2026, reporting $50,000 in lobbying income.

Lobbying for Jazz Pharmaceuticals, Inc. · Specialty pharmaceuticals

As filed: AVENUE SOLUTIONS for JAZZ PHARMACEUTICALS, INC.

All filings by Avenue Solutions · Everything Jazz Pharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing, including orphan drugs; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders

Medicare/Medicaid

Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.